Author Archives: Taylor Mercado

PMID:  In Vivo. 2009 Nov-Dec;23(6):959-67. PMID: 20023240 Abstract Title:  Chemosensitizing effect of nordihydroguaiaretic acid and its tetra-acetylated derivative on parental and multiresistant TA3 mouse mammary adenocarcinoma cells. Abstract:  BACKGROUND: Multidrug resistance (MDR) continues being the major obstacle for successful anticancer chemotherapy.MATERIALS AND METHODS: The action of nordihydroguaiaretic acid (NDGA) and its tetra-acetylated derivative (NDGATA) on …

Continue reading “Chemosensitizing effect of nordihydroguaiaretic acid and its tetra-acetylated derivative on parental and multiresistant TA3 mouse mammary adenocarcinoma cells.”

PMID:  Prostate. 2008 Aug 1 ;68(11):1232-40. PMID: 18491370 Abstract Title:  Inhibitory effects of nordihydroguaiaretic acid (NDGA) on the IGF-1 receptor and androgen dependent growth of LAPC-4 prostate cancer cells. Abstract:  BACKGROUND: Nordihydroguaiaretic acid (NDGA) is an inhibitor of the IGF-1 receptor (IGF-1R) in breast and other cancers, and concomitantly inhibits tumor growth both in cultured …

Continue reading “Inhibitory effects of nordihydroguaiaretic acid (NDGA) on the IGF-1 receptor and androgen dependent growth of LAPC-4 prostate cancer cells.”

PMID:  Lab Invest. 2012 Dec ;92(12):1777-87. Epub 2012 Oct 8. PMID: 23044922 Abstract Title:  Nordihydroguaiaretic acid inhibition of NFATc1 suppresses osteoclastogenesis and arthritis bone destruction in rats. Abstract:  Nordihydroguaiaretic acid (NDGA) is known to have prominent anticancer activity against several cancers, and is also known to be an inhibitor of 5-lipoxygenase (5-LO). In this study, …

Continue reading “Nordihydroguaiaretic acid inhibition of NFATc1 suppresses osteoclastogenesis and arthritis bone destruction in rats.”

PMID:  J Cell Biochem. 2007 Dec 15 ;102(6):1529-41. PMID: 17486636 Abstract Title:  Nordihydroguaiaretic acid inhibits insulin-like growth factor signaling, growth, and survival in human neuroblastoma cells. Abstract:  Neuroblastoma is a common pediatric malignancy that metastasizes to the liver, bone, and other organs. Children with metastatic disease have a less than 50% chance of survival with …

Continue reading “Nordihydroguaiaretic acid inhibits insulin-like growth factor signaling, growth, and survival in human neuroblastoma cells.”

PMID:  Molecules. 2019 Jul 19 ;24(14). Epub 2019 Jul 19. PMID: 31330936 Abstract Title:  Intake of Molecular Hydrogen in Drinking Water Increases Membrane Transporters,-Glycoprotein, and Multidrug Resistance-Associated Protein 2 without Affecting Xenobiotic-Metabolizing Enzymes in Rat Liver. Abstract:  Molecular hydrogen (H) has been shown to have antioxidant and anti-inflammatory activities that may reduce the development and …

Continue reading “Intake of hydrogen-rich water may increase the efflux of xenobiotics or toxic substances from the liver into bile.”

PMID:  Cancer Lett. 1987 Oct 30 ;37(2):139-46. PMID: 3119189 Abstract Title:  Nordihydroguaiaretic acid suppression of rat mammary carcinogenesis induced by N-methyl-N-nitrosourea. Abstract:  The activity of the lipoxygenase inhibitor, nordihydroguaiaretic acid (NDGA), as a cancer chemopreventive agent in the rat mammary gland was determined. Beginning 1 week after a single i.v. dose of 20 or 50 …

Continue reading “Nordihydroguaiaretic acid suppression of rat mammary carcinogenesis induced by N-methyl-N-nitrosourea.”

PMID:  Mol Cancer Ther. 2008 Jul ;7(7):1900-8. PMID: 18645000 Abstract Title:  Nordihydroguaiaretic acid, a cytotoxic insulin-like growth factor-I receptor/HER2 inhibitor in trastuzumab-resistant breast cancer. Abstract:  The majority of patients with HER2-overexpressing metastatic breast cancer who initially respond to the HER2-targeted antibody trastuzumab show disease progression within 1 year. The identification of novel agents that effectively …

Continue reading “Nordihydroguaiaretic acid, a cytotoxic insulin-like growth factor-I receptor/HER2 inhibitor in trastuzumab-resistant breast cancer.”

PMID:  Life Sci. 2004 Sep 24 ;75(19):2341-51. PMID: 15350831 Abstract Title:  Nordihydroguaiaretic acid-induced Ca2+ handling and cytotoxicity in human prostate cancer cells. Abstract:  The effect of nordihydroguaiaretic acid (NDGA), a compound commonly used as a lipoxygenases inhibitor, on intracellular free Ca2+ levels ([Ca2+]i) in PC3 human prostate cancer cells was investigated. [Ca2+]i was measured by …

Continue reading “Nordihydroguaiaretic acid-induced Ca2+ handling and cytotoxicity in human prostate cancer cells.”

PMID:  Breast Cancer Res Treat. 2005 Nov ;94(1):37-46. PMID: 16142439 Abstract Title:  Nordihydroguaiaretic acid (NDGA) inhibits the IGF-1 and c-erbB2/HER2/neu receptors and suppresses growth in breast cancer cells. Abstract:  Nordihydroguaiaretic acid (NDGA) is a phenolic compound isolated from the creosote bush Larrea divaricatta that has anti-cancer activities both in vitro and in vivo. We can …

Continue reading “Nordihydroguaiaretic acid inhibits the IGF-1 and c-erbB2/HER2/neu receptors and suppresses growth in breast cancer cells.”

PMID:  Oncol Lett. 2011 Jan ;2(1):123-128. Epub 2010 Nov 10. PMID: 22870140 Abstract Title:  Nordihydroguaiaretic acid inhibits growth of cervical cancer SiHa cells by up-regulating p21. Abstract:  Nordihydroguaiaretic acid (NDGA) and its derivatives possess anti-cancer effects on various types of cancer via the induction of apoptosis or cell cycle arrest. This study proved that NDGA …

Continue reading “Nordihydroguaiaretic acid inhibits growth of cervical cancer SiHa cells by up-regulating p21.”